Yasuo Adachi, Naoko Yoshio-Hoshino and Norihiro Nishimoto Pages 247 - 255 ( 9 )
Prognosis of multiple myeloma (MM) remains insufficient despite the intervention of high dose chemotherapy with auto- or allo- hematopoietic stem cell transplantation and the advent of molecular target drugs such as thalidomide, lenalidomide, and bortezomib. Further development or new concepts of therapeutic approaches are still required for MM treatment. Current standard protocol for MM treatment does not include gene delivery method or oncolytic virus approaches. Since MM is a disorder originated from B cell lineage, it involves immunological aspects in both pathogenesis and clinical manifestations. Therefore, the comprehension of immunology as well as oncology is essential to exploit new therapeutic approaches. Recently, novel therapeutic concepts for MM have been emerging. In this review, we present current progress of gene therapy related to MM treatments as well as the overview of MM treatment history.
Gene therapy, myeloma cell, growth factor, IL-6, IL-6 receptor, tocilizumab, new receptor inhibitor of IL-6 (NRI)
Laboratory of Immune Regulation,Graduate School of Frontier Biosciences, Osaka University, 1-3, Yamadaoka, Suita City, Osaka Prefecture, Japan.